Retatrutide vs Tirzepatide
A triple agonist against the dual incretin agonist — what the third receptor changes.
The short answer: Retatrutide adds a glucagon receptor arm on top of the GIP/GLP-1 pair that tirzepatide targets.
Retatrutide
Tirzepatide
Compound in Mounjaro® · Zepbound®Side by side
| Property | Retatrutide | Tirzepatide |
|---|---|---|
| Research category | Metabolic Research | Metabolic Research |
| Presentation | 4mg × 4 pens | 2.5mg × 4 pens |
| Dosage options | 4mg × 4 pens · 8mg × 4 pens · 12mg × 4 pens | 2.5mg × 4 pens · 5mg × 4 pens · 10mg × 4 pens · 15mg × 4 pens |
| Approved medicine using it | None — investigational | Mounjaro® · Zepbound® |
| Availability | In stock | In stock |
| Batch COA | Supplied with order | Supplied with order |
| From | €357.90 | €324.90 |
How they differ
Tirzepatide binds two incretin receptors, GIP and GLP-1. Retatrutide binds those two plus the glucagon receptor, which is the entire reason it is described as a triple agonist rather than a dual one.
That third arm is the interesting part in the research literature. Glucagon receptor activation is associated with increased energy expenditure, whereas the GIP and GLP-1 arms act mainly on insulin secretion, gastric emptying and central satiety pathways. The three mechanisms are therefore additive rather than redundant.
Tirzepatide has completed the SURPASS and SURMOUNT programmes and is an approved medicine. Retatrutide remains investigational, with no marketed brand anywhere, which is why this catalogue lists a brand equivalent for one and not the other.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. Brand names are trademarks of their respective owners and are referenced only to identify the active compound — no affiliation or equivalence is claimed.